ANAPTYSBIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.61 USD | -3.38% |
|
+5.21% | +14.99% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 37.13M | Sales 2025 * | 25.68M | Capitalization | 696M |
|---|---|---|---|---|---|
| Net income 2024 * | -165M | Net income 2025 * | -203M | EV / Sales 2024 * | 10.6 x |
| Net cash position 2024 * | 304M | Net cash position 2025 * | 314M | EV / Sales 2025 * | 14.8 x |
| P/E ratio 2024 * |
-4.26
x | P/E ratio 2025 * |
-4.14
x | Employees | 117 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on AnaptysBio, Inc.
More recommendations
More press releases
| 1 day | -0.51% | ||
| 1 week | -2.90% | ||
| Current month | +4.64% | ||
| 1 month | +19.35% | ||
| 3 months | +5.68% | ||
| 6 months | +78.61% | ||
| Current year | +18.91% |
1 week
23.41
26.22
1 month
18.4927.02
Current year
18.4927.50
1 year
13.3627.50
3 years
13.3637.89
5 years
10.0079.09
10 years
10.00134.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.02% | 1,487 M€ | +9.08% | - | |
| 0.02% | 430 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 24.63 | -3.30% | 46 072 |
| 24-05-16 | 25.47 | -0.51% | 184,130 |
| 24-05-15 | 25.6 | +1.35% | 216,018 |
| 24-05-14 | 25.26 | +5.29% | 272,554 |
| 24-05-13 | 23.99 | +2.48% | 433,285 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
2024-06-12
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.47
USD
Average target price
43.78
USD
Spread / Average Target
+71.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.91% | 696M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.12% | 22.28B | |
| -11.90% | 22.41B | |
| -5.66% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- ANAB Stock